We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Sharks in the water

15 October 2007 By Robert Cyran

Despite chalking up good stock returns of late, Carl Icahn was able to kick the biotech into a sale. Big pharma’s hunger for acquisitions has emboldened activists. Now larger rivals like Amgen may look like targets, too. But at some $25bn, Biogen may be the upper limit in size.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)